 |
SV Life Sciences Fund IVSVLSF IV closed in February 2007 with total commitments of $550 million (plus $22 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010 the Fund had invested $316 million in 37 portfolio companies. To go to individual portfolio companies websites please click on company logo. SV Life Sciences Fund IV (SVLSFIV)
Accelecare Wound Centers: US
First Investment: 2007 - Buyout Accelecare provides full service management, operation and medical team staffing of wound healing and hyperbaric medicine centers at hospitals throughout the South Central and Central portion of the US. 
Adimab: US
First investment: 2007 - Start Up Adimab, Inc. is developing a fully integrated platform for antibody discovery and manufacturing which will offer customers/ acquirers a 3rd party royalty free and very rapid, 2-3 month path from target to optimized antibody. 
Affinium Pharmaceuticals : US
First investment: 2007 - Early Stage Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis pathway. 
Allocure: US
First investment: 2008 - Early Stage Allocure is a biotechnology company at the forefront of innovative cell therapies for the treatment of acute kidney injury. 
Altura Medical: US
First investment: 2008 - Seed Altura is a seed stage company within Intersect Partners developing a low profile stent graft for the treatment of abdominal aortic aneurysms (AAA). Formerly known as Altura Interventional. Antiva: UK First investment: 2008 - Start Up Antiva, is a spin out business from Vantia www.vantiatherapeutics.com and alongside that business focuses on leading research based healthcare into improving clinical treatments through development & commercialisation of innovative medicines. 
Cardiomind: US
First Investment: 2007 - Early Stage CardioMind is a medical device company developing novel nitinol-based stents and an innovative, balloon-free stent delivery system for small, difficult-to-access vessels. 
Celerion: US
First investment: 2010 - Start Up Celerion is the privately owned CRO formed through the acquisition of the development and regulatory services consultancy and early clinical development operations of MDS Pharma Services. 
CR: US
First Investment: 2008 - Buyout CR is a holding company whose management team intends to develop a global CRO providing outsourced clinical monitoring, data management and other related services for biotechnology and pharmaceutical companies conducting Phase II-IV clinical trials. The first of CR’s transactions included Trio Clinical Research (www.trioclinicalresearch.com), an innovative clinical research services company. 
CRI Worldwide: US
First Investment: 2007 - Buyout CRI Worldwide, founded in 2000, is a CNS focused network of clinical research facilities conducting phase I-III trials (mostly inpatient studies). CRI operates research units in partnership with local area hospitals providing “flexible” bed arrangements and yet they are able to use a central IRB. 
Delenex Therapeutics: Switzerland
First investment SVLSF IV: 2009 - Early Stage Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in to its antibody fragments for delivering next generation Therapeutics application. 
Entellus: US
First investment: 2006 - Early Stage Entellus is a company developing medical device therapies for nasal and sinus disease. 
EUSA Pharma : UK
First investment: 2007 - Expansion EUSA Pharma (EUSA) is a fast growing, transatlantic specialty pharma company developing and commercialising for healthcare professionals and patients a range of prescription products in pain, oncology and critical care. 
Halscion: US
First Investment: 2007 - Seed Halscion is seed-stage company founded by The Innovation Factory which is developing a biomaterial for wound management. ISG Holdings: US First investment: 2008 - Seed ISG Holdings is a business offering workers compensation scheme outsourcing by businesses with US operations. 
Itero Biopharmaceuticals: US
First investment: 2007 - Early Stage Itero is an early stage biosimilars company focused on the large number of product opportunities with product patents. 
Juvaris BioTherapeutics: US
First Investment: 2009 - Early Stage Developing novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. 
LenSx Lasers, Inc: US
First Investment: 2008 - Start Up LenSx is developing a novel computer controlled, femtosecond laser system that can integrate multiple refractive surgical procedures performed in the cornea and lens. 
Link Medicine: US
First Investment: 2008 - Early Stage Link Medicine is a clinical stage company spun out of Harvard University working on disease-modifying therapies for neurodegenerative diseases. 
Logical Therapeutics: US
First investment: 2007 - Start Up Logical Therapeutics is a clinical stage drug development company with a focus on inflammation. The lead product, LT-NS001, is a prodrug of naproxen designed to minimize GI toxicity. The company is also working on a prodrug of aspirin, also designed to minimize GI toxicity. MindFrame: US First investment: 2007 - Seed MindFrame is a seed stage company formed out of Intersect Partners developing a novel mechanical device for the treatment of ischemic stroke. 
Mpex Pharmaceuticals: US
First SVLSF IV Investment: 2009 - Early Stage Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex’s first product will be an inhaled antibiotic for serious lung infections. 
NeurogesX (NGSX): US
First Investment: 2007 - PIPE NeurogesX is developing novel topical products to relieve chronic pain and improve quality of life. 
NKT Therapeutics, Inc: US
First Investment: 2007 - Early Stage NKT Therapeutics is a biotechnology company focused on developing therapeutics based on a unique subset of immune cells called natural killer T (”NKT”) cells. 
Ocular Therapeutix: US
First Investment: 2008 - Start Up I-Therapeutix is a medical device company that is currently engaged in development of in situ formed hydrogel therapeutic products specifically for ophthalmology. Formerly known as I-therapeutics . 
Ophthotech: US
First investment: 2007 - Seed Ophthotech is dedicated to developing drugs for ophthalmic diseases with high unmet medical needs. PanOptica First investment: 2009 - Seed PanOptica is a start-up company dedicated to developing drugs for ophthalmic diseases with high unmet medical needs. 
ReShape: US
First investment: 2005 - Seed ReShape is a seed stage project within the Intersect Partners incubator developing an endoscopically placed device for the treatment of obesity. 
RespiVert: UK - Exited
First Investment: 2007 - Start Up RespiVert is a discovery company focused on Chronic obstructive pulmonary disease ('COPD') and severe asthma. The company’s goal is to develop novel inhaled and intranasal drugs for respiratory disorders with high unmet medical need and high commercial potential based on novel insights on biology and chemistry. 
Sadra Medical: US
First investment: 2003 - Seed Sadra based in Campbell, CA, is developing an innovative new approach to aortic valve disease through a minimally invasive percutaneous replacement solution. Spectrum Professional Services: US First investment: 2007 - Buyout Spectrum Professional Services is building a suite of services to provide to nursing homes and other long term care facilities on an outsourced basis. The initial platform acquisition is focused on the contract rehabilitation therapy area. 
TransEnterix: US
First Investment: 2007 - Early Stage TransEnterix is developing a surgical platform that provides all the benefits of a multi-port laparoscopic surgical approach while retaining a single port of entry through a natural body orifice or via the umbilicus. 
ValenTx: US
First investment: 2009 - Early Stage ValenTx, Inc., a medical device company, develops less invasive treatments for morbid obesity. 
Vantia Pharmaceuticals: UK
First investment: 2008 - Start Up Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines. 
Vitalize Consulting Solutions: US
First Investment: 2007 - Buyout Vitalize Consulting Solutions, Inc. provides the highest quality clinical and business solutions to healthcare organizations across the United States and Canada. Their main focus is in the areas of application implementation and enhancement, process optimization, interfaces, project management, technology and integration, training and knowledge transfer. 
X2-Pharma: Germany - Exited
First investment: 2008 - Seed X2-Pharma is a biopharmaceutical company dedicated to the discovery and development of small molecule pharmaceuticals for the treatment of inflammatory diseases. 
| |
